Literature DB >> 31338634

Orphan drug development: the increasing role of clinical pharmacology.

Mariam A Ahmed1,2, Malek Okour3, Richard Brundage4,5, Reena V Kartha4,5.   

Abstract

Over the last few decades there has been a paradigm shift in orphan drug research and development. The development of the regulatory framework, establishment of rare disease global networks that support drug developments, and advances in technology, has resulted in tremendous growth in orphan drug development. Nevertheless, several challenges during orphan drug development such as economic constraints; insufficient clinical information; fewer patients and thus inadequate power; etc. still exist. While the standard regulatory requirements for drug approval stays the same, applications of scientific judgment and regulatory flexibility is significantly important to help meeting some of the immense unmet medical need in rare diseases. Clinical pharmacology presents a vital role in accelerating orphan drug development and overcoming some of these challenges. This review highlights the critical contributions of clinical pharmacology in orphan drug development; for example, dose finding, optimizing clinical trial design, indication expansion, and population extrapolation. Examples of such applications are reviewed in this article.

Entities:  

Keywords:  Model informed drug discovery and development; Modeling and simulations; Orphan drugs; Rare diseases

Mesh:

Year:  2019        PMID: 31338634     DOI: 10.1007/s10928-019-09646-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  60 in total

Review 1.  Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.

Authors:  Venkatesh A Bhattaram; Brian P Booth; Roshni P Ramchandani; B Nhi Beasley; Yaning Wang; Veneeta Tandon; John Z Duan; Raman K Baweja; Patrick J Marroum; Ramana S Uppoor; Nam Atiqur Rahman; Chandrahas G Sahajwalla; J Robert Powell; Mehul U Mehta; Jogarao V S Gobburu
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

2.  A general model for the origin of allometric scaling laws in biology.

Authors:  G B West; J H Brown; B J Enquist
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

3.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Authors:  Haihui Yu; Bill Burton; Chien-Jung Huang; Jennings Worley; Dong Cao; James P Johnson; Art Urrutia; John Joubran; Sheila Seepersaud; Katherine Sussky; Beth J Hoffman; Fredrick Van Goor
Journal:  J Cyst Fibros       Date:  2012-01-30       Impact factor: 5.482

5.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Authors:  Jeffrey Hyams; Wallace Crandall; Subra Kugathasan; Anne Griffiths; Allan Olson; Jewel Johanns; Grace Liu; Suzanne Travers; Robert Heuschkel; James Markowitz; Stanley Cohen; Harland Winter; Gigi Veereman-Wauters; George Ferry; Robert Baldassano
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

6.  Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

Authors:  Cary G Sauer; Subra Kugathasan
Journal:  Med Clin North Am       Date:  2010-01       Impact factor: 5.456

7.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 8.  Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs.

Authors:  G Labrecque; J P Bureau; A E Reinberg
Journal:  Pharmacol Ther       Date:  1995-05       Impact factor: 12.310

9.  A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov.

Authors:  Stuart A Bell; Catrin Tudur Smith
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

10.  A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Authors:  Koichiro Yoneyama; Christophe Schmitt; Naoki Kotani; Gallia G Levy; Ryu Kasai; Satofumi Iida; Midori Shima; Takehiko Kawanishi
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

View more
  5 in total

Review 1.  A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?

Authors:  Simona Ronchetti; Emira Ayroldi; Erika Ricci; Marco Gentili; Graziella Migliorati; Carlo Riccardi
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

Review 2.  Opportunities and Challenges for Machine Learning in Rare Diseases.

Authors:  Sergio Decherchi; Elena Pedrini; Marina Mordenti; Andrea Cavalli; Luca Sangiorgi
Journal:  Front Med (Lausanne)       Date:  2021-10-05

Review 3.  Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.

Authors:  Annette S Gross; Anya C Harry; Christine S Clifton; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2022-02-17       Impact factor: 3.716

Review 4.  Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Vanessa Dos Reis Ferreira; Paula A Videira; And Gonçalo Valadão
Journal:  Genes (Basel)       Date:  2019-11-27       Impact factor: 4.096

Review 5.  One drug to treat many diseases: unlocking the economic trap of rare diseases.

Authors:  Karolina Pierzynowska; Teresa Kamińska; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2020-09-14       Impact factor: 3.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.